ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 131

Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population

Michael Pham1, Giovanni Orsolini 2, Cynthia Crowson 3, Melissa Snyder 1, Rajiv Pruthi 4 and Kevin Moder 5, 1Mayo Clinic, Rochester, MN, 2University of Verona, Verona, Italy, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, 5Mayo Clinic Rochester, rochester, MN

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antiphospholipid, Antiphospholipid antibodies, antiphospholipid syndrome and anticoagulation, Diagnostic Tests

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC.  Some have suggested a clinically useful role for aPS-PT as a potential surrogate marker for the LAC – especially in the clinical scenario of concurrent anticoagulation where the LAC can have decreased diagnostic performance.  However, the studies revealing the aPS-PT and LAC relationship have primarily been carried out on well-established APS and SLE cohorts.  Validation studies replicating this relationship in a real-world, all-comer study population are lacking.  The purpose of this study was to determine the sensitivity and specificity of aPS-PT to the LAC and other APS serologies in an all-comer population undergoing evaluation for APS and other autoimmune syndromes.

Methods: A cross-section of patients from June 2017 to December 2018 undergoing evaluation for APS across all medical specialties were reviewed for APS testing inclusive of LAC, aPS-PT, anti-cardiolipin (aCL), and anti-β2 glycoprotein-1 (β2GP1).  Presence of a LAC was determined by trained hematologists interpreting mixing and neutralization studies. Demographic details were abstracted from the medical record.  Cases meeting the SLICC criteria for SLE and the revised Sapporo criteria for APS were enumerated.  Sensitivities, specificities, negative-, and positive predictive values with 95% confidence intervals were calculated.

Results: A sample of 166 eligible patients was identified. Mean age was 49±17 years.  Seventy-one percent were female, 89% Caucasian, 15% with SLE, and 21% with APS.  At time of testing, 18% were on warfarin, 8% on direct factor Xa inhibitors and 1% on low-molecular weight heparin.  The aPS-PT was found to be the most specific to the LAC as seen in table 1.  Specificity of IgG aPS-PT was 100% (96-100%) and IgM aPS-PT was 97% (91-100%) to the LAC.  This corresponds to a positive predictive value for IgG aPS-PT of 100% (89-100%) and IgM aPS-PT of 95% (84-99%).  Specificities of aPS-PT to aCL and β2GP1 antibodies were slightly less in the 80% range.  In contrast, the sensitivities of aPS-PT to the LAC were only in the 40-50% range.

Conclusion: In our study with an all-comer population undergoing evaluation for APS and other autoimmune syndromes, aPS-PT had high specificity and high positive predictive value to the presence of the LAC.  The sensitivity and negative predictive performance of aPS-PT to LAC however was less robust.  This study’s findings echo similar findings in past studies on APS and SLE cohorts.  And, it corroborates the notion that a positive aPS-PT could be a clinically useful marker for the LAC in the general clinical setting.


zACR_PSPT LAC association_PDF TABLE


Disclosure: M. Pham, None; G. Orsolini, None; C. Crowson, Crescendo Bioscience, 5, Crescendo BioScience Inc., 5, Crescendo Bioscience Inc., 5, Crescendo Biosciences inc., 5, Pfizer, 2; M. Snyder, None; R. Pruthi, None; K. Moder, None.

To cite this abstract in AMA style:

Pham M, Orsolini G, Crowson C, Snyder M, Pruthi R, Moder K. Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/anti-phosphatidylserine-prothrombin-antibodies-as-a-predictor-of-the-lac-in-an-all-comer-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-phosphatidylserine-prothrombin-antibodies-as-a-predictor-of-the-lac-in-an-all-comer-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology